TD Asset Management Inc Buys 11,930 Shares of Kymera Therapeutics, Inc. $KYMR

TD Asset Management Inc increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 5.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 221,178 shares of the company’s stock after purchasing an additional 11,930 shares during the quarter. TD Asset Management Inc’s holdings in Kymera Therapeutics were worth $17,210,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after purchasing an additional 1,833 shares during the period. Millennium Management LLC raised its holdings in shares of Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the period. Invesco Ltd. raised its holdings in shares of Kymera Therapeutics by 13.8% in the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after purchasing an additional 5,809 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $265,000.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 price target on shares of Kymera Therapeutics in a report on Thursday, April 30th. BTIG Research lowered their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $117.14.

Kymera Therapeutics Trading Down 0.2%

Kymera Therapeutics stock opened at $73.95 on Tuesday. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $103.00. The firm has a market capitalization of $6.08 billion, a price-to-earnings ratio of -20.71 and a beta of 2.02. The firm has a 50 day simple moving average of $82.88 and a 200 day simple moving average of $79.87.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same period in the previous year, the business earned ($0.82) EPS. Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. On average, equities research analysts forecast that Kymera Therapeutics, Inc. will post -3.3 EPS for the current year.

Insiders Place Their Bets

In related news, Director Bruce Booth sold 5,900 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the transaction, the director directly owned 5,641 shares in the company, valued at approximately $507,464.36. The trade was a 51.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jeremy G. Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the completion of the transaction, the chief operating officer owned 61,202 shares of the company’s stock, valued at $4,737,646.82. This represents a 59.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 260,115 shares of company stock worth $21,218,138 in the last three months. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.